ChipDx Eyeing FDA Submission for Breast Cancer Relapse Test

The firm has received pre-IDE evaluations from the FDA for BreastGeneDx and is currently looking for partners to help it during the next stage of assay validation.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories